We report on our single-center experience with pancreas transplantation alone (PTA) in 71 patients with type 1 diabetes, and a 4-year follow-up. Portal insulin delivery was used in 73.2% of cases and enteric drainage of exocrine secretion in 100%. Immunosuppression consisted of basiliximab (76%), or thymoglobulin (24%), followed by mycophenolate mofetil, tacrolimus, and low-dose steroids. Actuarial patient and pancreas survival at 4 years were 98.4% and 76.7%, respectively. Relaparatomy was needed in 18.3% of patients. Restored endogenous insulin secretion resulted in sustained normalization of fasting plasma glucose levels and HbA1c concentra-tion in all technically successful transplantations. Protenuria (24-hour) improved significantly after PTA. Renal function declined only in recipients with pretransplant glomerular filtration rate (GFR) greater than 90 ml/min, possibly as a result of correction of hyperfiltration following normalization of glucose metabolism. Further improvements were recorded in several cardiovascular risk factors, retinopathy, and neuropathy. We conclude that PTA was an effective and reasonably safe procedure in this single-center experience.
Introduction
ancreas transplantation is a clinical option in the treatment of patients with type 1 diabetes (T1D) [1] [2] [3] . This procedure may be considered as a group of three separate clinical entities: simultaneous pancreas and kidney transplantation (SPK), pancreas after kidney (PAK), and pancreas transplant alone (PTA) [1] [2] [3] . It has been shown that SPK, by inducing insulin independence and replacing native renal function, has beneficial effects on diabetes complications and prolongs life expectancy [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] .
The usefulness of pancreas transplantation alone (PTA) in T1D patients without advanced nephropathy (GFR ≥ 50 ml/min) is debated [1] [2] [3] [5] [6] [7] [8] . It is generally accepted that patients are eligible for a PTA if they have:
1. a history of frequent, acute, and severe metabolic complications (hypoglycemia, hyperglycemia, ketoacidosis) requiring medical intervention, or 2. severe clinical and emotional problems with exogenous insulin therapy that are incapacitating, or 3. consistent failure of insulin-based management to prevent acute complications [11] .
PTA may also be considered for T1D patients who have a high risk of secondary diabetic complications (nephropathy, retinopathy, neuropathy), as proposed by a few authors and scientific diabetes societies [1] [2] [3] 12] . Recent studies reported that after PTA the 5-year patient survival is 90% [13] , and that pancreas graft half-life is 9 years [6] . Sustained normoglycemia improves several microvascular diabetic complications [1-3, 10, 14, 15] . Although, it might not prolong life expectancy compared with patients on the waiting list [5] [6] [7] [8] . Furthermore, immunosuppressant nephrotoxicity is expected to cause, or expedite, the progression of diabetic nephropathy towards end-stage renal failure [1-3, 16, 17] .
With all this in mind, we conducted an evaluation of our results following PTA in seventy-one T1D patients. Safety and efficacy were monitored throughout follow-up, with special attention to proteinuria and native kidney function.
Patients and methods
The aim of this study was to define safety and efficacy of PTA in T1D patients receiving a PTA at a single institution. Safety was defined as patient survival, lack of major adverse events, and preservation of renal function. Efficacy was defined as transplant ability to induce and maintain insulin independence, and evidence of a positive effect on the course of microvascular diabetic complications, with special attention to diabetic nephropathy. Forty patients (56%) received antihypertensive therapy (angiotensin-converting enzyme inhibitors, calcium channel blockers, beta-blockers, or a combination thereof), and eleven of them (15%) received lipid-lowering agents (mainly statins). PTA was indicated in 19 patients (27%) because of hyperlabile diabetes, defined as poor metabolic control with frequent episodes of unawareness hypoglycemia, despite intensive insulin regimens. In the remaining patients, poor metabolic control was accompanied by varying degrees of microvascular diabetic complications. According to previous studies [1] [2] [3] , an estimated GFR of ≥ 50 ml/min was required to become eligible for PTA. No per-protocol pancreas or renal biopsies were performed.
Patients' characteristics
Pancreas donors had the following characteristics: -Age: 26.6 yrs (range 5 to 55). 
Abbreviations:
ACE -angiotensin-converting enzyme BMI -body mass index CMV -cytomegalovirus E/A velocity -ratio between early (E) and late (atrial -A) ventricular filling velocity EC-MPA -enteric-coated mycophenolic acid GFR -glomerular filtration rate HbA1c -glycated hemoglobin HDL -high-density lipoprotein HLA -human leukocyte antigen IU -international unit LDL -low-density lipoprotein MMF -mycophenolate mophetil MNSI -Michigan Neuropathy Screening Instrument PAK -pancreas after kidney transplantation PANCREAS -Pancreas Allotransplantation for Diabetic Nephropathy and Mild Chronic REnal fAilure Stage Study PTA -pancreas transplantation alone RR -relative risk SD -standard deviation SPK -simultaneous pancreas and kidney transplantation T1D -type 1 diabetes Tx -transplantation UNOS -United Network of Organ Sharing Mean pancreas cold ischemia time was 11 hours and 36 minutes (range 8 to 18 hours).
Transplantation procedures
A detailed description of the surgical techniques employed at our institution for pancreas transplantation was reported previously [18, 19] . Briefly, all grafts were placed in the space behind the ascending colon and its mesentery. Enteric exocrine drainage was used in all recipients, while venous effluent was created either in the portal system (73.2%), or in the systemic circulation (26.8%). All patients received an induction treatment, consisting of basiliximab (20 mg) (Simulect, Novartis, Basel, Switzerland) in 54 recipients (76%), or antithymocyte globulin (1 mg/kg/day) (Thymoglobulin, Genzyme Corporation, Cambridge, MA) in the remaining 17 recipients (24%). The first dose of either antibody was administered before graft reperfusion. Thymoglobulin was given for 7 consecutive days, with the daily dose held if the total leukocyte count was <2,500/mm 3 , or if the lymphocyte count was <100/mm 3 . The same maintenance therapy, including tacrolimus (Prograf, Astellas Pharma, Tokio, Japan), mycophenolate mophetil (MMF, CellCept, Roche, Basel, Switzerland), or mycophenolic acid (EC-MPA, Novartis, Basel, Switzerland), together with steroids, were given to all recipients. The dose of tacrolimus was adjusted to maintain blood through levels of 10-15 ng/ml during the first month, and of 8-12 ng/ml thereafter. MMF and EC-MPA were given at the highest tolerated dose (initial dose of 2 g/day of MMF and 1440 mg/day of EC-MPA), mainly based on hematologic toxicity and gastrointestinal side effects.
At the last follow-up control, tacrolimus through levels were 8.8 ± 1.8 ng/ml, whereas MMF and EC-MPA doses were 1.3 ± 0.4 g/day and 0.9 ± 0.2 g/day, respectively. Steroids were tapered to 5 mg/day at 3 months post-transplantation. Finally, all patients received antimicrobial, antiviral, and antithrombotic prophylaxis as previously detailed [18, 19] .
Follow-up assessment
Upon discharge, patients were followed up monthly up to six months post-transplantation, every three months up to 1 year, and every 6 months thereafter, unless otherwise necessary. The pancreas graft was considered functionally competent as long as fasting blood glucose, random blood glucose level, and glycated hemoglobin concentration (HbA1c) were within the normal range without any pharmacological antidiabetic therapy.
For the purpose of the present study, the following parameters were assessed before and 1, 2, 3, and 4 years post-transplantation: -body weight, -blood pressure (measured three times with a sphygmomanometer after sitting position for at least 10 minutes; the mean of the last two measurements was recorded), Complete cardiac evaluation, including Doppler echocardiography (Sonos 5500 echograph; Agilent Technologies, Andover, MA), was performed, with geometric, systolic, and diastolic parameters computed, as described earlier [20] . Renal function, proteinuria, retinopathy, and neuropathy were evaluated, as detailed previously [14, 15, [20] [21] [22] .
Statistical analysis
Data are presented as mean ± standard deviation (SD 
Results

Patient and pancreas survival
As shown in Figure 1 , Kaplan-Meier survival analysis showed that patient and pancreas (full insulin-independence) survivals were respectively 98.4% and 85.5% at 1 yr, 98.4% and 79.7% at 2 yr, 98.4% and 78.3% at 3 yr, and 98.4% and 76.7% at 4 yr. One patient died 5 months after transplant due to disseminated CMV disease. No patient developed cardiovascular events, or morbidities, other than those reported in this and the following paragraphs. The actual 4-year rates for patient and pancreas survival (24 patients with this follow-up) were 98.2% and 77.1%, respectively. Among patients with a functioning pancreas graft at 1 yr, 88.7% were still insulin-independent at the 4-year follow-up control.
Overall, 10 recipients developed vascular thrombosis, with occlusions occurring in 3 of them. No vein thrombosis extended beyond the site of anastomosis between donor and recipient vessels. Thus, no patient needed caval, or portal, thrombectomy.
Repeat surgery was necessary in 13 patients (18.2%). In detail, relaparotomy was required because of bleeding (6 recipients, 8.4%), occlusive vascular thrombosis (3 recipients, 4.2%), hyperacute rejection (3 recipients, 4.2%), and duodenal graft anastomotic leak (1 recipient, 1.4%). Clinically relevant infections (requiring assistance from our center) developed in 11 patients (15.5%), 5 were bacterial and 6 CMV infections (including the fatal case mentioned above).
Three patients experienced hyperacute rejection. Diagnosis was confirmed after allograft pancreatectomy through histological findings and a sudden rise in donor-specific antibodies. Fifteen acute rejection episodes were recorded in 14 patients: In these patients, rejection was suspected because of a more than two-fold elevation in pancreatic enzymes in the absence of other possible ex-planations. Rejection was biopsy-proven in all patients, graded according to Drachenberg et al. [23] , and successfully treated (excluding the 3 hyperacute episodes) with a 10 day course of monoclonal antibody therapy [24] . During the follow-up, 12 recipients were eventually diagnosed with chronic allograft rejection. Seven of them were previously diagnosed with one (n = 6), or two (n = 1), episodes of acute rejection. All patients presented deteriorating metabolic control, but usually with some degree of residual function (C-peptide range, 0.8 to 2.3 ng/ml). Diagnosis was based on pancreas biopsy and/or evidence of persisting donor-specific antibodies. Figure 2 shows fasting plasma glucose, HbA1c, and fasting C-peptide concentrations before transplantation and at 1, 2, 3, and 4 years posttransplantation in patients with functioning grafts. Normalization of glucose values without exogenous insulin administration was rapidly achieved, and solidly maintained throughout the study period in all successful cases. Total and LDL-cholesterol levels decreased significantly after transplantation without change in HDLcholesterol and triglyceride levels ( Table 1) . These results were achieved without major changes in the use of statins (18.6% before transplantation vs. 26% at 4 years). Prior and 4-year systolic and diastolic blood pressure values (mmHg) were 129 ± 10 and 115 ± 6 (p < 0.01), and 82 ± 8 and 73 ± 7 (p < 0.01) respectively. Any antihypertensive treatment (ACE inhibitors in 92% of cases) before transplantation (42%) was maintained until the end of the 4-year follow-up (50%).
Effects on glycemic control and kidney function
Overall, proteinuria decreased from 1.36 ± 2.72 g/day (pre-transplant) to 0.29 ± 0.51 g/day (last control post-transplant; p < 0.01). Serum creatinine concentrations increased from 0.95 ± 0.28 to 1.17 ± 0.26 mg/dl (p < 0.01). GFR, calculated according to the Cockroft-Gault formula, decreased by approximately 20% from 94 ± 39 to 75 ± 22 ml/min (p < 0.01). Further analyses were performed in patients who reached the 4-year followup examination, based on the pre-transplant GFR, > or ≤ 90 ml/min (Figure 3 ). Renal function decreased significantly in patients with a GFR above 90 ml/min, whereas GFR remained substantially unchanged in patients with GFR below 90 ml/min.
A similar analysis was performed depending on the presence or absence of proteinuria (Table 2 ). In non-albuminuric patients, 2 developed microalbuminuria, and kidney function declined significantly over time, with an overall average GFR decrease of 17 ml/min in the first year, and 2.7 ml/min/year in the follow-up. Of the 6 patients with microalbuminuria prior to transplantation (daily urinary protein excretion 0.23 ± 0.05 g), 3 patients became normoalbuminuric, 2 patients remained microalbuminuric, and 1 subject developed macroproteinuria. Their creatinine levels and GFR showed evidence of deterioration, but without reaching statistical significance ( Table 2 ). In this group, GFR decreased by 15.1 ml/min during the first year, and 2.87 ml/min per year thereafter. Eleven patients were macroproteinuric (2.97 ± 3.55 g/day) before transplantation. At the end of the 4-yr follow-up period, more than half of them showed reduction or even disappearance of proteinuria (Table 2). GFR decrease in these patients was slow (3.4 ml/min per year), although significant at 4 years post-transplantation.
Effects on cardiac function, retinopathy, and neuropathy
Cardiac parameters, assessed by doppler echocardiographic examinations, were within the normal range, and similar to those reported for a local According to the grading methods, and the results previously reported at an earlier follow-up control [14] , PTA had beneficial effects on diabetic retinopathy. Before transplantation, 7.5% of patients had no retinopathy, and all of them remained lesion-free at 4 years. Of the 29.5% patients with non-proliferative retinopathy, 75% improved and 25% remained unchanged. Finally, in the group of patients with proliferative and/or laser-treated retinopathy, lesions remained stable in 82% of patients and progressed to a more serious grade in the remaining 18%.
As shown in Table 3 , neuropathy assessment showed a significant improvement in several indices of peripheral and autonomic responses after PTA.
Discussion
We have reported on a single center experience with PTA focusing on the effects of PTA up to 4 years after transplantation. We assessed metabolic parameters, cardiovascular risk factors, renal function and proteinuria (i.e. diabetic nephropathy), and chronic diabetic complications. Patient survival and insulin independence rates are similar to, or even slightly better than, those reported in other contemporary series [1] [2] [3] . Our improved outcomes may in part be explained by a close follow-up, mostly carried out at our institution. It confirms that current PTA regimens are largely safe (in terms of patient survival) and effective (in terms of graft function).
Normalization of plasma glucose concentrations was solid and sustained, as documented by HbA1c level stability within normal ranges. Moreover, improvement of several cardiovascular risk factors, previously reported after a shorter followup period [20] , was maintained after 4 years post-PTA. Non-significant 14% and 8% declines in LDL-cholesterol, 1 and 2 years after PTA, have been previously reported in a small group of patients (n = 11) with systemic venous drainage of endocrine secretion of the graft [25] . It remains unclear whether the portal or the systemic drainage of insulin may further improve lipid levels [26, 27] , but it is a fascinating hypothesis based on solid theoretical grounds.
We found a significant decrease in proteinuria levels after PTA and a 20% cumulative decrease of GFR over the 4 years of follow-up. Similar rates of GFR loss after 5 years post-PTA have been recently reported, with no major difference, irrespective of which calcineurin inhibitor was used [17] . Interestingly, in the present study, the loss of renal function after PTA was less significant in patients with lower baseline GFR (< 90 ml/min) than in patients with higher pristine renal function (GFR > 90 ml/min). Possibly, patients from the latter group were already in the stage of hyperfiltration at the time of PTA, and this seemed to result in higher renal function. Should this interpretation be correct, a moderate GFR decline after PTA could actually mean improvement of renal function as a result of correction of hyperfiltration. Renal histology could not be performed routinely before or after PTA as our institutional policy does not favor protocol biopsies. Nevertheless, it is known that long-term normoglicemia (> 10 years) improves renal histology after PTA, despite GFR reduction from a mean of 108 ± 20 ml/min/1.73 m 2 before PTA to 74 ± 14 ml/min/1.73 m 2 10 years after PTA [28, 29] . Therefore, our observation could either mirror an early stage of this process that is possibly not yet evident in histology, or it could identify a subgroup of patients in whom normalization of metabolic control results in earlier clinical benefit. Regarding the question why proteinuria declined after PTA, it is possible that normalization of blood glucose and restored C-peptide secretion may play a role, as previously discussed [15] . Reduction in glucose levels is associated with decreased hyperfiltration and diminished albuminuria [30, 31] . C-peptide exerts beneficial actions on the endothelium in the diabetic kidney [32] . The effects of PTA on the reduction of proteinuria may be of particular relevance. Notably, very recent data show that the risk of end-stage renal disease remains high and unchanged despite renoprotective treatments [33] . This finding may suggest the need for new therapies in diabetic patients with overt diabetic nephropathy.
It is conceivable that the normoglycemic condition and the improvements in other parameters (lipids and blood pressure) have contributed to the mitigation of chronic diabetic complications. Evidence for improved ventricular ejection fraction, as assessed by echocardiography, confirmed our initial report in fewer patients with shorter follow-up [20] . It should however be noted that echocardiography parameters were mostly normal before PTA. This is possibly due to stringent candidate selection and an earlier indication to PTA, as compared to SPK. Consequently, no conclusion can be drawn on the question whether improvements in the already satisfactory cardiac function in PTA recipients translates into the same survival benefits seen in SPK recipients [1] [2] [3] .
In a report dealing with a follow-up of approximately 2 years, it was observed that diabetic retinopathy improved, or stabilized, in the majority of T1D patients after PTA, with a substantial benefit against non-transplanted subjects [14] . Our study confirms these results and shows that improvement in retinopathy is maintained at the longer follow-up period of 4 years, as already observed after SPK [34, 35] . Also, our series of PTA confirms the positive impact on diabetic neuropathy, as previously reported after SPK, PAK, and PTA [36] . This was the case for both peripheral and autonomic lesions. These observations have not been made with current intensive insulin treatment [37] .
Overall, the improvements seen in the clinical course of diabetic complications indicate that normalization of metabolic control improves microvascular complications in PTA recipients. Basically, this should mean that PTA recipients have a longer life expectancy than non-transplanted patients continuing on exogenous insulin supply, despite similar baseline medical conditions. Demonstration of this hypothesis would require a welldesigned prospective randomized comparison. The most reliable information that is currently available comes from two independent retrospective analyses of the UNOS data base. Interestingly, small differences in methodology lead to opposite conclusions. In the first of these surveys, Venstrom et al. reported an increased risk of mortality for PTA recipients (RR 1.57 at 4 years), as compared to patients on the wait list [5] . In the second survey, Gruessner et al. [6] [7] [8] extended the followup period, excluded patients listed at multiple centers, and included deaths occurred shortly after withdrawal from the wait list. In this analysis, the authors could not confirm the increased risk of mortality for PTA recipients.
Hopefully, answers to the many pending questions surrounding PTA may eventually be provided by the recently implemented PANCREAS study, a prospective multi-institution study randomizing selected T1D patients to PTA, or intensive insulin. treatment [38] . Until new data are available, current information suggest that PTA may be a beneficial option in selected T1D patients. This seems to be particularly true when considering T1D patients with established markers of decreased survival such as neuropathy, severe retinopathy, or proteinuria. Since renal func-
